Search results
Results from the WOW.Com Content Network
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. [2] It is used by mouth or intravenously. [2] It is available as a generic medication. [4] [5]
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain
The drug or other substance has a currently accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV. The complete list of Schedule V substances is as follows.
Vimpat 28 October 2008 [65] lamotrigine: Lamictal 27 December 1994 [66] October 1991 [46] [51] May 1995 [51] levetiracetam: Keppra 30 November 1999 [67] 29 September 2000 [46] [68] 29 September 2000 [68] mephenytoin: Mesantoin 23 October 1946 [69] metharbital: Gemonil 1952 [70] [71] methsuximide: Celontin
Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales. Abbreviations are used in the list as follows: INN = International Nonproprietary Name
Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. [1] It is classified as a serotonin modulator [1] and is taken by mouth.
Generic drug production is a large part of the pharmaceutical industry in China. Western observers have said that China lacks administrative protection for patents. [79] However, entry to the World Trade Organization has brought a stronger patent system. [80]
The US Food and Drug Administration (FDA) approved cenobamate in November 2019, and granted the application for Xcopri to SK Life Science Inc. [7] [8] [9] [16] In January 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization ...